Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for severe COVID-19 pneumonia
NL-OMON50069Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and pneumonia comparing Tocilizumab + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Clinical status at Day 28. Started Apr 2020; status: active, not recruiting.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on NL-OMON50069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50069.